Stocktoria
Cyclerion Therapeutics, Inc. CYCN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-03-18
Cyclerion Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -239.8% | -181.4% | — | -6242.4% | -1400.2% | -3539.4% | -2774.3% | — |
| Net margin | -170.1% | -152.8% | — | -14841.1% | -1310.2% | -3388.6% | -2729.3% | — |
| FCF margin | — | — | — | -13673.7% | -926.5% | -3223.6% | -2420.7% | — |
| Return on assets | -35.3% | -31.9% | -39.4% | -243.8% | -87.0% | -67.4% | -66.0% | -1557.2% |
| Return on equity | -38.8% | -34.5% | -46.6% | -421.7% | -107.0% | -130.8% | -125.9% | 1103.4% |
| Current ratio | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 | 3.45 | 5.55 | 0.05 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.